Sanofi, Regeneron Report Positive Phase 1b Data for Dupilumab in Atopic Dermatitis
Posted on March 02, 2013 at 10:47 AM EST
Sanofi (NYSE: SNY ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting